Coherus Oncology (NASDAQ:CHRS) Releases Earnings Results, Misses Estimates By $0.03 EPS

Coherus Oncology (NASDAQ:CHRS) posted its earnings results on Monday. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.03), FiscalAI reports.

Coherus Oncology Price Performance

Shares of NASDAQ CHRS traded up $0.11 during trading on Monday, reaching $1.93. The company had a trading volume of 2,183,524 shares, compared to its average volume of 2,544,500. Coherus Oncology has a 52 week low of $0.71 and a 52 week high of $2.62. The business’s 50 day moving average price is $1.77 and its 200-day moving average price is $1.54. The stock has a market cap of $288.48 million, a PE ratio of 1.45 and a beta of 1.05. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.23 and a current ratio of 1.24.

Analyst Ratings Changes

Separately, Oppenheimer started coverage on Coherus Oncology in a report on Thursday, January 22nd. They set an “outperform” rating and a $10.00 price target for the company. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $5.51.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of CHRS. Geode Capital Management LLC increased its holdings in Coherus Oncology by 0.8% in the second quarter. Geode Capital Management LLC now owns 2,676,476 shares of the biotechnology company’s stock valued at $1,958,000 after purchasing an additional 20,976 shares during the last quarter. Panagora Asset Management Inc. raised its position in shares of Coherus Oncology by 17.8% in the 4th quarter. Panagora Asset Management Inc. now owns 1,620,271 shares of the biotechnology company’s stock valued at $2,301,000 after acquiring an additional 244,303 shares during the period. Hudson Bay Capital Management LP grew its holdings in Coherus Oncology by 3.1% during the fourth quarter. Hudson Bay Capital Management LP now owns 835,000 shares of the biotechnology company’s stock valued at $1,186,000 after purchasing an additional 25,000 shares during the period. UBS Group AG increased its stake in Coherus Oncology by 38.5% in the third quarter. UBS Group AG now owns 795,941 shares of the biotechnology company’s stock valued at $1,305,000 after purchasing an additional 221,410 shares in the last quarter. Finally, Millennium Management LLC acquired a new stake in Coherus Oncology in the fourth quarter worth $938,000. Institutional investors own 72.82% of the company’s stock.

About Coherus Oncology

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.